tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

GRTX Stock Latest News

Galera Therapeutics price target lowered to $6 from $10 at H.C. Wainwright
The FlyGalera Therapeutics price target lowered to $6 from $10 at H.C. Wainwright
2d ago
GRTX
Biotech Alert: Searches spiking for these stocks today
The FlyBiotech Alert: Searches spiking for these stocks today
7d ago
APLS
ESPR
Biotech Alert: Searches spiking for these stocks today
The FlyBiotech Alert: Searches spiking for these stocks today
8d ago
CDMO
CRBP
Galera Therapeutics price target lowered to $12 from $18 at Citi
The FlyGalera Therapeutics price target lowered to $12 from $18 at Citi
8d ago
GRTX
Galera Therapeutics announces presentation of analysis of Phase 3 ROMAN trial
The FlyGalera Therapeutics announces presentation of analysis of Phase 3 ROMAN trial
14d ago
GRTX
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
Press ReleasesGalera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
14d ago
GRTX
These 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts
Stock Analysis & IdeasThese 2 ‘Strong Buy’ Penny Stocks Are Poised for a Massive Rally, Say Analysts
16d ago
GRTX
OABI
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
Press ReleasesGalera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
16d ago
GRTX
Galera Therapeutics reports Q4 EPS (58c), consensus (54c)
The FlyGalera Therapeutics reports Q4 EPS (58c), consensus (54c)
16d ago
GRTX
Galera Therapeutics initiated with an Overweight at Piper Sandler
The FlyGalera Therapeutics initiated with an Overweight at Piper Sandler
1M ago
GRTX
Galera Therapeutics upgraded to Buy from Underperform at BofA
The FlyGalera Therapeutics upgraded to Buy from Underperform at BofA
1M ago
GRTX
Galera Therapeutics sells 14.32M shares at $2.095 in registered direct offering
The FlyGalera Therapeutics sells 14.32M shares at $2.095 in registered direct offering
1M ago
GRTX
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
Press ReleasesGalera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
1M ago
GRTX
Galera announces FDA acceptance, priority review of Avasopasem NDA
The FlyGalera announces FDA acceptance, priority review of Avasopasem NDA
1M ago
GRTX
Biotech Alert: Searches spiking for these stocks today
The FlyBiotech Alert: Searches spiking for these stocks today
2M ago
ACHV
CLLS
Galera Therapeutics submits NDA for avasopasem for SOM
The FlyGalera Therapeutics submits NDA for avasopasem for SOM
3M ago
GRTX
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
Press ReleasesGalera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
3M ago
GRTX
Galera Therapeutics price target lowered to $18 from $20 at Citi
The FlyGalera Therapeutics price target lowered to $18 from $20 at Citi
4M ago
GRTX
Galera Therapeutics expects cash to fund operations into 2H23
The FlyGalera Therapeutics expects cash to fund operations into 2H23
5M ago
GRTX
Galera Therapeutics reports Q3 EPS (60c), consensus (52c)
The FlyGalera Therapeutics reports Q3 EPS (60c), consensus (52c)
5M ago
GRTX
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
Press ReleasesGalera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
5M ago
GRTX
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
Press ReleasesGalera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
5M ago
GRTX
Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Press ReleasesGalera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
7M ago
GRTX
Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer
Press ReleasesGalera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer
7M ago
GRTX
Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates
Press ReleasesGalera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates
8M ago
GRTX
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
Press ReleasesGalera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
9M ago
GRTX
What Triggered Galera’s 2X Stock Surge?
Market NewsWhat Triggered Galera’s 2X Stock Surge?
1y ago
GRTX
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.